<DOC>
	<DOCNO>NCT00186680</DOCNO>
	<brief_summary>Evaluate feasibility safety autologous transplantation CD34+Thy-1+ hematopoietic stem cell afer high dose marrow ablative chemotherapy patient breast cancer .</brief_summary>
	<brief_title>CD34 Selection Peripheral Blood Stem Cell Graft Autologous Transplant</brief_title>
	<detailed_description>Selection CD34+THY-1 Positive Cells From Peripheral Blood Cells Procured Autologous Hematopoietic Support Following High Dose Treatment BCNU , Cyclophosphamide &amp; Cisplatin Stage IV Breast Cancer &amp; Limited Prior Treatment</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<criteria>stage IV breast cancer primary breast cancer express CD34+ adequate organ function evidence active infection chemotherapy within 4 week CNS disease</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>February 2010</verification_date>
</DOC>